COMMUNIQUÉS West-GlobeNewswire

Shire plc : Form 8 (DD) - Gail Fosler
02/07/2018
FORM 8 (DD) PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS) Rules 8.1, 8.2 and 8.4 of the Takeover Code (the "Code") [...]
Shire plc : Form 8 (DD) - Steven Gillis
02/07/2018
FORM 8 (DD) PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS) Rules 8.1, 8.2 and 8.4 of the Takeover Code (the "Code") [...]
Shire plc : Form 8 (DD) - David Ginsburg
02/07/2018
FORM 8 (DD) PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS) Rules 8.1, 8.2 and 8.4 of the Takeover Code (the "Code") [...]
Shire plc : Form 8 (DD) - Sara Mathew
02/07/2018
FORM 8 (DD) PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS) Rules 8.1, 8.2 and 8.4 of the Takeover Code (the "Code") [...]
Shire plc : Form 8 (DD) - Ian Clark
02/07/2018
FORM 8 (DD) PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS) Rules 8.1, 8.2 and 8.4 of the Takeover Code (the "Code") [...]
Shire plc : Form 8 (DD) - Susan Kilsby
02/07/2018
FORM 8 (DD) PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS) Rules 8.1, 8.2 and 8.4 of the Takeover Code (the "Code") [...]
Shire plc : Form 8 (DD) - Olivier Bohuon
02/07/2018
FORM 8 (DD) PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS) Rules 8.1, 8.2 and 8.4 of the Takeover Code (the "Code") [...]
Shire plc : CHMP RECOMMENDS EU MARKETING AUTHORIZATION FOR VEYVONDI(R) FOR ADULTS WITH VON WILLEBRAND DISEASE
02/07/2018
CHMP RECOMMENDS EU MARKETING AUTHORIZATION FOR VEYVONDI ® [VONICOG ALFA, RECOMBINANT VON WILLEBRAND FACTOR] FOR ADULTS WITH VON WILLEBRAND DISEASE If approved, VEYVONDI ® [ vonicog alfa, recombinant von Willebrand [...]
OSE Immunotherapeutics Receives IDMC Approval to Continue “Atalante 1” Phase 3 NSCLC Clinical Trial of Tedopi®
02/07/2018
Trial in Non-Small Cell Lung Cancer (NSCLC) Patients After Immune Checkpoint Inhibitor Failure Checkpoint Inhibitor Failures Is an Unmet Need in Non-Small Cell Lung Cancer Patient Population NANTES, France, July 02, [...]
ESPERITE N.V. (ESP) SELLS ITS STAKE IN CRYOSAVE SOUTH AFRICA TO GO LIFE HEALTHCARE (GLI).
02/07/2018
CryoSave in its joint venture with Ecsponent (ECS) at equal participation have sold 100% of their stake for ZAR 50,000,000 (Fifty Million South African Rand). As a leading stem cells bank, CryoSave SA will continue to [...]
Adamis Pharmaceuticals Announces Distribution and Commercialization Agreement for Symjepi
02/07/2018
SAN DIEGO, July 01, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Adamis”) announced today that it has entered into an exclusive distribution and commercialization agreement with Sandoz Inc [...]
Align Technology Provides Update Regarding SmileDirectClub (SDC) Dispute
30/06/2018
Judge Denies SDC’s Request for Temporary Injunction SAN JOSE, Calif., June 29, 2018 (GLOBE NEWSWIRE) -- Align Technology, Inc. (Nasdaq:ALGN) today provided an update to its April 25, 2018 disclosure regarding SDC [...]
MedMira Reports Third Quarter Results
30/06/2018
HALIFAX, Nova Scotia, June 29, 2018 (GLOBE NEWSWIRE) -- MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended April 30, 2018. Q3 FY2018 Financial Results Highlights Profit and [...]
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
30/06/2018
CAMBRIDGE, Mass., June 29, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat [...]
Neon Therapeutics Announces Closing of Initial Public Offering
29/06/2018
CAMBRIDGE, Mass., June 29, 2018 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq:NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced the closing of its initial [...]
Acura Pharmaceuticals Announces First Quarter 2018 Financial Results
29/06/2018
PALATINE, Ill., June 29, 2018 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTC PINK:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the three months [...]
TESARO Draws $200 Million From Second Tranche of Non-Dilutive Term Loan Financing
29/06/2018
WALTHAM, Mass., June 29, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology focused biopharmaceutical company, announced today that it has drawn the $200 million second tranche under its term loan [...]
Aeglea BioTherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
29/06/2018
AUSTIN, Texas, June 29, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare [...]
RavenQuest Lists Warrants
29/06/2018
VANCOUVER, British Columbia, June 29, 2018 (GLOBE NEWSWIRE) -- RavenQuest BioMed Inc. (CSE:RQB) (OTCQB:RVVQF) (Frankfurt:1IT) ( “ RavenQuest ”) is pleased to announce that warrants issued pursuant to its February 28, [...]

Pages